IP Library Granted Patent US 11,052,153
Granted Patent B2
US 11,052,153 · App. 16/153,893 · Granted Jul 6, 2021

Highly branched alpha-D-glucans

Inventors: Yuan Yao (West Lafayette, IN); Jingmin Joanne Zhang (West Lafayette, IN)
Assignee: Purdue Research Foundation
A61K47/36A61K8/73A61K31/192A61K31/343A61Q19/00C08B37/0009A61K2800/49A61K2800/544
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,052,153
App. No.
16/153,893
Granted
Jul 6, 2021
Kind
B2
Abstract

Compositions including a highly branched alpha-D-glucan or modified forms thereof and a solute compound are described herein. The compositions can provide increased water solubility and/or increased rate of dissolution for the solute compound. The compositions can also provide increased stability for the solute compound. Methods for preparing and using compositions including a solute compound and a highly branched alpha-D-glucan are also described.

Claims (19)

1. A modified highly branched alpha-D-glucan having greater than 4% branch density, the modified highly branched alpha-D-glucan comprising octenyl succinate, the modified highly branched alpha-D-glucan further comprising hydroxypropyl, hydroxyethyl, polyethylene glycol, polypropylene glycol, or combinations thereof.

2. The modified highly branched alpha-D-glucan according to claim 1 and further comprising at least one substitution group selected from the group consisting of antibody, antigen, aptamer, protein, peptide, amino acid, cyclodextrin, saccharide, lipid, nucleic acid and nucleotide, dendrimer, enzyme, fluorescent group or dye, magnetic group, metal ion, metal nanoparticle, quantum dot, polymer and block copolymer, radioactive group, and combinations thereof.

3. The modified highly branched alpha-D-glucan according to claim 1 prepared by at least one treatment selected from the group consisting of acid hydrolysis, oxidation, pyrodextrinization, enzymatic treatment using alpha-amylase, beta-amylase, debranching enzyme, transglucosidase, amyloglucosidase, and/or protease, bleaching, shear force treatment, extrusion, kneading, homogenization, hydrothermal processing, dry heating, microwave treatment, radiation, and combinations thereof.

4. The modified highly branched alpha-D-glucan according to claim 1 which improves a property of a solute compound, wherein the property is selected from the group consisting of the aqueous solubility, dissolution rate, and stability against crystallization, oxidation, degradation, deterioration, reduction, or structure change, and combinations thereof.

5. A composition comprising a modified highly branched alpha-D-glucan according to claim 1 and a solute compound, the composition having increased solubility and/or stability of the solute compound, wherein the mass ratio of the solute compound to the modified highly branched alpha-D-glucan is from 100:1 to 1:1000.

6. The composition according to claim 5 , wherein the solute compound is an active hydrophobic compound selected from the group consisting of phytochemicals, carotenoids, extracts from plants, animals or microorganisms, and drugs.

7. The composition according to claim 5 , wherein the solute compound is synthetic or naturally-occurring phenolic moieties.

8. The composition according to claim 5 , wherein the solute compound is an active pharmaceutical ingredient.

9. The composition according to claim 5 , wherein the solute compound is selected from the group consisting of niclosamide, ivermectin, sirolimus, indomethacin, paclitaxel, griseofulvin, ibuprofen, quercetin, curcumin and thymol.

10. The composition according to claim 5 , wherein the ratio of solute compound to the modified highly branched alpha-D-glucan is about 1:3, wherein the modified highly branched alpha-D-glucan reduces the rate of amorphous-to-crystalline transforming of the solute.

11. The modified highly branched alpha-D-glucan according to claim 1 comprising octenyl succinate and hydroxypropyl.

12. The modified highly branched alpha-D-glucan according to claim 1 comprising octenyl succinate and one or more substituents selected from the group consisting of polypropylene glycol, polypropylene oxide and combinations thereof.

13. The modified highly branched alpha-D-glucan according to claim 1 comprising octenyl succinate and one or more substituents selected from the group consisting of polyethylene glycol, polyethylene oxide and combinations thereof.

14. The modified highly branched alpha-D-glucan according to claim 13 and comprising one or more additional substituents selected from the group consisting of polypropylene glycol, polypropylene oxide and combinations thereof.

15. The modified highly branched alpha-D-glucan according to claim 1 in which the modified highly branched alpha-D-glucan is a modified phytoglycogen or glycogen material.

16. The modified phytoglycogen or glycogen material of claim 15 comprising octenyl succinate and hydroxypropyl hydroxypropyl.

17. The modified phytoglycogen or glycogen material of claim 15 comprising octenyl succinate and one or more substituents selected from the group consisting of polypropylene glycol, polypropylene oxide and combinations thereof.

18. The modified phytoglycogen or glycogen material of claim 15 comprising octenyl succinate and one or more substituents selected from the group consisting of polyethylene glycol, polyethylene oxide and combinations thereof.

19. The modified phytoglycogen or glycogen material of claim 18 further comprising one or more substituents selected from the group consisting of polypropylene glycol, polypropylene oxide and combinations thereof.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jul 31, 2020
From: PURDUE UNIVERSITY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 053375/0860 →
Continuity (3)
Continuation 14395200
Provisional Application 61635453 · Apr 19, 2012
Related Publication 20190038753A1 · Feb 7, 2019